small molecule

LIVMARLI

MARALIXIBAT CHLORIDE

Loss of exclusivityOctober 2043latest FDA-listed patent expiry

CompanyMirum Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	LIVMARLI
Active ingredient	MARALIXIBAT CHLORIDE
Strength	EQ 15MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12296050	October 2043	product
11497745	February 2040	use U-4187
11229647	February 2040	use U-4187
11229661	October 2032	use U-4186
12350267	October 2032	use U-3973
10512657	October 2032	use U-4186
11376251	October 2032	use U-4187
11260053	May 2031	use U-4187

Regulatory exclusivity

Code	Expires
I-938	March 2027
NCE	September 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Mirum Pharmaceuticals